查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679341

吸入式生技药品市场规模、份额、趋势分析报告：按生技药品、应用、剂型、分销管道、地区、细分市场预测，2025-2030 年

Inhalable Biologics Market Size, Share & Trends Analysis Report By Biologics, By Application, By Dosage Form, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

吸入生技药品市场的成长与趋势

根据Grand View Research, Inc.的最新报告，全球吸入式生技药品市场规模预计到2030年将达到100.6亿美元，2025年至2030年期间的复合年增长率为17.6%。

该市场的成长动力包括呼吸系统疾病的日益普及、对非侵入性药物输送的需求不断增长以及增强生物稳定性的配方技术的进步。该市场受益于患者对自我给药的偏好、透过肺部输送更快的药物起效以及对吸入式单株抗体、胜肽和基于 RNAi 的疗法的研究。监管支援和技术创新将进一步扩大市场机会。

气喘、慢性阻塞性肺病和囊肿纤维化等呼吸系统疾病的高发生率仍是主要驱动因素。根据 CDC 和 ACAAI 的数据，到 2023 年，气喘将影响 7.7% 的美国（2,490 万人），导致医疗保健使用量和成本大幅增加。吸入生技药品可快速输送到肺部，增强治疗效果，同时最大限度地减少全身副作用。 Ocugen、Moderna、辉瑞-BioNTech 和阿斯特捷利康等公司正在透过吸入式疫苗和治疗方法扩大其产品组合。例如，Ocugen 于 2025 年 1 月在其第一阶段测试中获得了 FDA 对其吸入式 COVID-19 疫苗 OCU500 的批准，而 MannKind Corporation 在第三阶段测试取得积极结果后获得了印度监管部门的核准，并继续扩大 Afrezza 的市场。

市场管道依然活跃，吸入式生技药品主要针对呼吸系统疾病、糖尿病、感染疾病和癌症。一项值得注意的创新是使用两性离子聚合物功能化的脂质奈米颗粒 (LNP) 进行吸入式 mRNA 疗法，该疗法于 2024 年 11 月发表在《美国化学学会杂誌》上，并证明了稳定的雾化和有效的肺部输送。

2024 年 12 月，继美国和巴西之后，MannKind Corporation 和 Cipla Ltd. 获得了印度 CDSCO核准，允许其在印度使用成人 Afrezza（人类胰岛素）吸入粉剂。根据这项策略倡议，MannKind 将供应产品，而 Cipla 将负责行销和分销，预计将于 2025 年下半年发货。此次合作旨在加强 Afrezza 的全球影响力，尤其是在印度，那里有超过 7,400 万成年人患有糖尿病。 Afrezza 是一种非注射型速效胰岛素，可快速吸收并在两到三小时内起效，满足了患者对创新、以患者为中心的糖尿病管理解决方案的偏好。 Cipla 广泛的分销网络旨在增强印度各地患者的治疗机会并改善其治疗效果。安全措施包括对患有慢性肺病的患者要谨慎，因为有支气管痉挛的风险。

作为其在吸入式生技药品领域管线进展的一部分，Ab Initio Pharma 已作为银牌赞助商加入第 35 届肺部药物输送 (DDL) 会议，该会议将于 2024 年 12 月 11 日至 13 日在爱丁堡举行。此次加入标誌着一项策略性倡议，旨在突出药物输送解决方案，包括小分子、胜肽、寡核苷酸和基于 RNA 的疗法。会议的主要特色包括关于鼻腔 mRNA 递送的演示和关于吸入寡核苷酸的海报，重点介绍非侵入性治疗方法的创新。

这些倡议凸显了该公司致力于透过战略伙伴关係、监管部门核准和专注于慢性病和感染疾病的管道创新来扩大吸入治疗方法的可及性并加强其全球市场地位。

吸入生技药品市场报告重点

  • 按类型划分，肽蛋白领域由于其广泛的治疗应用、更高的稳定性和高效的肺部吸收，在 2024 年占据市场领先地位，收益占有率最大，为 29.85%。
  • 预测期内，RNAi 药物领域预计将以强劲的复合年增长率成长。
  • 根据应用，糖尿病领域在 2024 年占据了最大的市场收益占有率。然而，呼吸系统疾病预计在预测期内将以快速的复合年增长率增长。
  • 根据剂型，干粉吸入器在 2024 年占据最大的市场收益占有率。然而，雾化器部分预计在预测期内将经历最快的复合年增长率。
  • 按分销管道划分，医院药房部门在 2024 年占据最大的市场收益占有率。
  • 2024年12月，Cipla于2024年12月11日获得CDSCO核准，在印度独家分销和销售由MannKind Corporation开发的Afrezza（一种吸入式胰岛素製剂）。 Afrezza 是一种用于治疗第 1 型和第 2 型糖尿病的速效胰岛素製剂，是一种非注射替代品，可快速吸收并在两到三小时内起效。 Cipla 旨在利用其分销网络来提高糖尿病管理的可及性，从而改善印度各地患者的治疗效果。

目录

第一章调查方法与范围

第 2 章执行摘要

3. 吸入生技药品市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
  • 管道分析
    • 候选药物清单（1至3期）
    • 预测期内可能实现商业化的药物
    • 3 期药物预测
  • 使用案例分析

4. 吸入式生技药品市场：按类型分類的业务分析

  • 2024年和2030年的类型市场占有率
  • 类型细分仪表板
  • 2018 年至 2030 年按类型分類的市场规模、预测与趋势分析
  • 胜肽和蛋白质
  • 疫苗
  • 单株抗体
  • 基于RNAi的药物
  • 其他的

5. 吸入式生技药品市场的应用、商业分析

  • 2024年及2030年的应用市场占有率
  • 应用程式细分仪表板
  • 2018 年至 2030 年按应用分類的市场规模、预测与趋势分析
  • 呼吸系统疾病
  • 糖尿病
  • 癌症
  • 其他的

6. 吸入式生技药品市场（依剂型划分）及业务分析

  • 2024年及2030年剂型市场占有率
  • 剂型细分细分仪表板
  • 2018-2030 年剂型市场规模、预测及趋势分析
  • 干粉吸入器
  • 定量吸入器
  • 喷雾器
  • 其他的

7. 吸入式生技药品市场（依通路、业务分析）

  • 分销通路市场占有率，2024 年和 2030 年
  • 分销通路细分仪表板
  • 2018 年至 2030 年分销通路市场规模、预测与趋势分析
  • 医院药房
  • 零售药局
  • 网路药局

8. 吸入式生技药品市场：区域、估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030 年市场规模及预测趋势分析
  • 北美洲
    • 按国家/地区，2018 年至 2030 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Kamada Pharmaceuticals
    • MannKind Corporation
    • Ab Initio Pharma
    • Ocugen, Inc.
    • CanSino Biologics
    • AstraZeneca
Product Code: GVR-4-68040-530-0

Inhalable Biologics Market Growth & Trends:

The global inhalable biologics market size is anticipated to reach USD 10.06 billion by 2030 and is projected to grow at a CAGR of 17.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growth drivers include the increasing prevalence of respiratory diseases, rising demand for non-invasive drug delivery, and advancements in formulation technologies enhancing biologic stability. The market benefits from patient preference for self-administration, faster drug onset through pulmonary delivery, and research on inhalable monoclonal antibodies, peptides, and RNAi-based therapeutics. Regulatory support and technological innovations further expand market opportunities.

The high prevalence of respiratory conditions, including asthma, COPD, and cystic fibrosis, remains a key growth driver. According to the CDC and ACAAI, asthma affected 7.7% of Americans (24.9 million) in 2023, leading to significant healthcare utilization and costs. Inhalable biologics offer targeted lung delivery with rapid onset, enhancing treatment efficacy while minimizing systemic side effects. Companies such as Ocugen, Moderna, Pfizer-BioNTech, and AstraZeneca are expanding their portfolios through inhaled vaccines and therapeutics. For instance, Ocugen received FDA clearance in January 2025 for a Phase 1 trial of OCU500, an inhaled COVID-19 vaccine, while MannKind Corporation continues to expand Afrezza's reach, with Indian regulatory approval following positive Phase 3 trial results.

The market pipeline remains active, with inhalable biologics targeting respiratory diseases, diabetes, infectious diseases, and oncology. A notable innovation includes inhalable mRNA therapeutics using lipid nanoparticles (LNPs) functionalized with zwitterionic polymers, as published in the Journal of the American Chemical Society in November 2024, demonstrating stable nebulization and effective pulmonary delivery.

In December 2024, MannKind Corporation and Cipla Ltd. secured CDSCO approval for Afrezza (insulin human) Inhalation Powder for adults in India, following prior approvals in the U.S. and Brazil. Under this strategic initiative, MannKind will supply the product while Cipla manages marketing and distribution, with shipments expected by late 2025. The move aims to strengthen Afrezza's global presence, particularly in India, where over 74 million adults are affected by diabetes. Afrezza offers a non-injectable, rapid-acting insulin alternative, with quick absorption and a 2-3 hour effect, addressing patient preferences for innovative and patient-centric diabetes management solutions. Cipla's extensive distribution network is positioned to enhance access and improve patient outcomes across India. Safety measures include precautions for patients with chronic lung diseases due to the risk of bronchospasm.

As part of pipeline advancements in inhalable biologics, Ab Initio Pharma participated as a Silver Sponsor at the 35th Drug Delivery to the Lungs (DDL) Conference from December 11-13, 2024, in Edinburgh. This engagement represents a strategic initiative to highlight its drug delivery solutions, including small molecules, peptides, oligonucleotides, and RNA-based therapies. Key conference features include a presentation on intranasal mRNA delivery and a poster on inhaled oligonucleotides, emphasizing innovation in non-invasive treatment modalities.

These initiatives underscore a growing emphasis on expanding access to inhalable therapies and strengthening global market positions through strategic partnerships, regulatory approvals, and pipeline innovations focused on chronic and infectious diseases.

Inhalable Biologics Market Report Highlights:

  • Based on type, the peptides and proteins segment led the market with the largest revenue share of 29.85% in 2024, due to their broad therapeutic applications, stability improvements, and efficient pulmonary absorption.
  • The RNAi-based therapeutics segment is projected to grow at a robust CAGR over the forecast period.
  • Based on applications, the diabetes segment accounted with the largest market revenue share in 2024. However, respiratory diseases are expected to grow at a rapid CAGR over the forecast period.
  • Based on dosage form, the dry powder inhalers segment accounted for the largest market revenue share in 2024, aided by approved products in the segment. However, the nebulizers segment is expected to witness at the fastest CAGR over the forecast period.
  • Based on the distribution channel, the hospital pharmacies segment accounted for the largest market revenue share in 2024.
  • In December 2024, Cipla received CDSCO approval on December 11, 2024, to exclusively distribute and market Afrezza (inhaled insulin) in India, developed by MannKind Corporation. Afrezza is a rapid-acting insulin for type 1 and type 2 diabetes, offering a non-injectable alternative with quick absorption and a 2-3 hour effect. Cipla aims to enhance diabetes management accessibility, leveraging its distribution network to improve patient outcomes across India.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. Dosage Form
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Inhalable Biologics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis
    • 3.4.1. List of Drug Candidates (Phase 1 to Phase 3)
    • 3.4.2. Potential Drugs to be Commercialized in the Forecast Period
    • 3.4.3. Phase 3 Drug Forecast
  • 3.5. Case Study Analysis

Chapter 4. Inhalable Biologics Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Peptides and Proteins
    • 4.4.1. Peptides and Proteins Market, 2018 - 2030 (USD Million)
  • 4.5. Vaccines
    • 4.5.1. Vaccines Market, 2018 - 2030 (USD Million)
  • 4.6. Monoclonal Antibodies
    • 4.6.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
  • 4.7. RNAi-based Therapeutics
    • 4.7.1. RNAi-based Therapeutics Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 5. Inhalable Biologics Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Respiratory Diseases
    • 5.4.1. Respiratory Diseases Market, 2018 - 2030 (USD Million)
    • 5.4.2. COPD
      • 5.4.2.1. COPD Market, 2018 - 2030 (USD Million)
    • 5.4.3. Asthma
      • 5.4.3.1. Asthma Market, 2018 - 2030 (USD Million)
    • 5.4.4. Cystic Forbis
      • 5.4.4.1. Cystic Forbis Market, 2018 - 2030 (USD Million)
    • 5.4.5. Covid-19
      • 5.4.5.1. Covid-19 Market, 2018 - 2030 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Others Market, 2018 - 2030 (USD Million)
  • 5.5. Diabetes
    • 5.5.1. Diabetes Market, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Inhalable Biologics Market: Dosage Form Business Analysis

  • 6.1. Dosage Form Market Share, 2024 & 2030
  • 6.2. Dosage Form Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
  • 6.4. Dry Powder Inhalers
    • 6.4.1. Dry Powder Inhalers Market, 2018 - 2030 (USD Million)
  • 6.5. Metered Dose Inhalers
    • 6.5.1. Metered Dose Inhalers Market, 2018 - 2030 (USD Million)
  • 6.6. Nebulizers
    • 6.6.1. Nebulizers Market, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Inhalable Biologics Market: Dosage Form Business Analysis

  • 7.1. Dosage Form Market Share, 2024 & 2030
  • 7.2. Dosage Form Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Inhalable Biologics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Inhalable Biologics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Inhalable Biologics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Kamada Pharmaceuticals
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. MannKind Corporation
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Ab Initio Pharma
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Ocugen, Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. CanSino Biologics
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. AstraZeneca
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global inhalable biologics market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 5 Global inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 6 Global inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 7 Global inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 North America inhalable biologics market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 10 North America inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 11 North America inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 12 North America inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.S. inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 16 U.S. inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Canada inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 18 Canada inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 19 Canada inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 20 Canada inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 22 Mexico inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 23 Mexico inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 24 Mexico inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Europe inhalable biologics market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 27 Europe inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 28 Europe inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 29 Europe inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 UK inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 31 UK Inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 32 UK inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 33 UK inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Germany inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 35 Germany inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 37 Germany inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 France inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 39 France Inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 40 France inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 41 France inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Italy inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 43 Italy inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 44 Italy inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 45 Italy inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 Spain inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 47 Spain inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 48 Spain inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 49 Spain inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Norway inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 51 Norway Inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 52 Norway inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 53 Norway inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Denmark inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 55 Denmark inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 56 Denmark inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 57 Denmark inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Sweden inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 59 Sweden inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 60 Sweden inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 61 Sweden inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific inhalable biologics market, by country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Japan inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 68 Japan inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 69 Japan inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 70 Japan inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 China inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 72 China inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 73 China inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 74 China inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 India inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 76 India inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 77 India inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 78 India inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Australia inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 80 Australia inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 81 Australia inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 82 Australia inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 84 South Korea inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Korea inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 86 South Korea inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Thailand inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 88 Thailand inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 89 Thailand inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 90 Thailand inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America inhalable biologics market, by country, 2018 - 2030 (USD Million)
  • Table 92 Latin America inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 93 Latin America inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 94 Latin America inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 95 Latin America inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96 Brazil inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 97 Brazil inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 98 Brazil inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 99 Brazil inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100 Argentina inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 101 Argentina inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 102 Argentina inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 103 Argentina inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Inhalable biologics market, by country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109 South Africa inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 110 South Africa inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 111 South Africa inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 112 South Africa inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117 UAE inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 118 UAE inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 119 UAE inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 120 UAE inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121 Kuwait inhalable biologics market, by type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait inhalable biologics market, by application, 2018 - 2030 (USD Million)
  • Table 123 Kuwait inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
  • Table 124 Kuwait inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Inhalable biologics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Inhalable biologics market dynamics
  • Fig. 12 Inhalable biologics market: Porter's five forces analysis
  • Fig. 13 Inhalable biologics market: PESTLE analysis
  • Fig. 14 Biologic market, 2018 - 2030 (USD Million)
  • Fig. 15 Peptides and Proteins market, 2018 - 2030 (USD Million)
  • Fig. 16 Vaccines market, 2018 - 2030 (USD Million)
  • Fig. 17 Monoclonal Antibodies market, 2018 - 2030 (USD Million)
  • Fig. 18 RNAi-based Therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Applicationmarket, 2018 - 2030 (USD Million)
  • Fig. 21 Respiratory diseases market, 2018 - 2030 (USD Million)
  • Fig. 22 COPD market, 2018 - 2030 (USD Million)
  • Fig. 23 Asthma market, 2018 - 2030 (USD Million)
  • Fig. 24 Cystic Forbis market, 2018 - 2030 (USD Million)
  • Fig. 25 Covid-19 market, 2018 - 2030 (USD Million)
  • Fig. 26 Others market, 2018 - 2030 (USD Million)
  • Fig. 27 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 28 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Dosage Form market, 2018 - 2030 (USD Million)
  • Fig. 31 Dry Powder Inhalers market, 2018 - 2030 (USD Million)
  • Fig. 32 Metered Dose Inhalers market, 2018 - 2030 (USD Million)
  • Fig. 33 Nebulizers market, 2018 - 2030 (USD Million)
  • Fig. 34 Others market, 2018 - 2030 (USD Million)
  • Fig. 35 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 36 Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 37 Retail Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 38 Online Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 39 Inhalable biologics market revenue, by region
  • Fig. 40 Regional marketplace: Key takeaways
  • Fig. 41 Regional marketplace: Key takeaways
  • Fig. 42 North America inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. country dynamics
  • Fig. 44 U.S. inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 45 Canada country dynamics
  • Fig. 46 Canada inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 47 Mexico country dynamics
  • Fig. 48 Mexico inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 49 Europe inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 50 UK country dynamics
  • Fig. 51 UK inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 52 Germany country dynamics
  • Fig. 53 Germany inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 54 France country dynamics
  • Fig. 55 France inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 56 Italy country dynamics
  • Fig. 57 Italy inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 58 Spain country dynamics
  • Fig. 59 Spain inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 60 Norway country dynamics
  • Fig. 61 Norway inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 62 Sweden country dynamics
  • Fig. 63 Sweden inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 64 Denmark country dynamics
  • Fig. 65 Denmark inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 66 Asia Pacific inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 67 Japan country dynamics
  • Fig. 68 Japan inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 69 China country dynamics
  • Fig. 70 China inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 71 India country dynamics
  • Fig. 72 India inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 73 Australia country dynamics
  • Fig. 74 Australia inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 75 South Korea country dynamics
  • Fig. 76 South Korea inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 77 Thailand country dynamics
  • Fig. 78 Thailand inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 80 Brazil country dynamics
  • Fig. 81 Brazil inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 82 Argentina country dynamics
  • Fig. 83 Argentina inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 84 MEA inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 85 South Africa country dynamics
  • Fig. 86 South Africa inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 87 Saudi Arabia country dynamics
  • Fig. 88 Saudi Arabia inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 89 UAE country dynamics
  • Fig. 90 UAE inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 91 Kuwait country dynamics
  • Fig. 92 Kuwait inhalable biologics market, 2018 - 2030 (USD Million)
  • Fig. 93 Company categorization
  • Fig. 94 Company market position analysis
  • Fig. 95 Strategic framework